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We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an
irreversible stasis of tumour blood flow (TBF) and subsequent loss of nutrient supply to tumour tissue. Since early 2002, under the
new designation AVE8062, AC7700 has undergone clinical trials in Europe and the US. Questions remain, however, concerning how
AC7700 blocks TBF and why the TBF stasis does not recover. In this study, using a rat tumour LY80, a variant of Yoshida sarcoma, we
examined whether TBF cessation after AC7700 administration is due to a direct action of the agent on tumour blood vessels. We
constructed electrodes that can drop a small quantity of the drug solution directly at the site of blood flow measurement and inserted
them subcutaneously and into the tumour. We compared the blood flow responses of normal vessels and tumour vessels after
administration of 10-ml doses of various concentrations (0.2, 1, 10, and 50mgml
 1) of the AC7700 solution. In addition, we assessed
TBF stasis after i.v. and intra-arterial 10mgkg
 1 AC7700 administration in an LY80-induced kidney tumour. To determine why the
TBF stasis is irreversible, we observed AC7700-induced changes in host arterioles and the tumour vascular network of the Sato lung
carcinoma using a vital microscopic rat transparent chamber. Since an increase in tumour interstitial fluid pressure brings about a
decrease in TBF, we also measured 10mgkg
 1 AC7700-induced changes in this pressure. The sensitivity of the blood flow response
after intratumoral application of AC7700 was markedly higher in normal vessels relative to tumour vessels. Intra-arterial
administration of AC7700 did not have stronger effects on TBF stasis than did i.v. administration. Intravital microscopy showed that
AC7700 induced a powerful and long-lasting constriction of host arterioles, so that complete stasis of blood flow occurred in
downstream vessels, which supplied blood to tumours. Owing to this stasis, the lumens of numerous tumour vessels narrowed or
completely disappeared, and numerous erythrocytes stagnated in drainage vessels of the tumour vascular network. Haemolysis of
these erythrocytes occurred after 2–3h, resulting in complete thrombosis. There was no indication of reperfusion in vessels showing
haemolysis. This haemolysis is thought to be the main cause for the irreversibility of TBF stasis. Since the tumour interstitial fluid
pressure decreased after i.v. AC7700 administration, the possibility of stasis of TBF being caused by tumour vascular compression was
excluded. All these results strongly suggest that the main target of AC7700 is host arterioles and that the stasis of TBF induced by
AC7700 is not triggered by a direct action of the drug on tumour vessels.
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Combretastatin A-4 (CA-4) is an antimitotic agent with in vitro
inhibitory action on tubulin polymerisation. It was first isolated
from the bark of the South African bush willow by Pettit et al
(1989), after which the water-soluble prodrug combretastatin A-4
phosphate (CA-4-P) was synthesised (Pettit et al, 1995), and the
effects of CA-4 were studied in vivo (Dark et al, 1997).
Combretastatin A-4 was determined to have strong suppressive
effects on tumour blood flow (TBF) (Tozer et al, 1999), and its
ability to induce widespread necrosis of solid tumours was
described in several studies (Dark et al, 1997; Beauregard et al,
1998; Horsman et al, 1998; Tozer et al, 1999; Zhao et al, 1999;
Landuyt et al, 2000; Malcontenti-Wilson et al, 2001). Recently,
Tozer et al (2001, 2002) reported the mechanism of action of CA-4-
P, which is currently undergoing phase I and phase II clinical trials
(Dowlati et al, 2002).
As the structure of CA-4 is simple, many derivatives have been
synthesised since the discovery of this substance by Pettit et al
(1989). In recent years, AC7700, a combretastatin analogue, was
developed in Japan (Hatanaka et al,1 9 9 8 ;O h s u m iet al, 1998) and
was found to have more powerful TBF stasis effects (Hori et al,
unpublished data) and antitumour effects (Nihei et al, 1999b)
compared with CA-4-P. Using subcutaneously (s.c.) transplanted
tumours in rodents and histological methods, we previously showed
that not only is AC7700 effective and suppresses tumour prolifera-
tion (Hori et al, 1999; Nihei et al, 1999a) but it also significantly
prolongs survival in tumour-bearing rats (Hori et al, 1999). AC7700
works both in rapidly proliferating transplanted tumours and in
relatively slowly proliferating primary tumours induced by chemical
carcinogens (Hori et al, 2001). Recently, such effectiveness was
confirmed in tumours growing within internal organs, including the
liver, kidney, and stomach, as well as in metastatic lymph nodes and Received 3 March 2003; revised 4 July 2003; accepted 14 July 2003
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ssmall 2.5-mm-diameter foci (Hori et al, 2002), which suggests that
these effects might be obtained in all types of solid tumours. Since
early 2002, AC7700 has been undergoing clinical trials in Europe and
the US under the new code name AVE8062.
It is clear that the strong antitumour effects of AC7700 are due
to blocking of the nutritional supply to the tumour by means of
TBF stasis, but many questions remain about the exact mechanism
of the stasis. The stasis may be brought about by a direct action of
AC7700 on the tumour vessels. Alternatively, the stasis may occur
indirectly via the host’s vascular response. However, in vivo
demonstration of this effect has not been achieved. Moreover, it
remains uncertain why TBF does not easily recover after the stasis.
The purposes of the present study were four-fold: (a) to
determine whether the cause of TBF stasis induced by AC7700 is
the result of a direct action of this agent on tumour vessels; (b) to
determine by means of intravital microscopy why the drug-
induced stasis is irreversible; (c) to determine whether AC7700,
like CA-4-P, can increase tumour vessel permeability and thereby
increase tumour interstitial fluid pressure (TIFP); and (d) to
construct a self-consistent model of the various phenomena
observed after AC7700 administration and thereby elucidate the
microcirculatory mechanisms that lead to irreversible TBF stasis
and subsequent necrosis.
MATERIALS AND METHODS
Rats and tumours
Male Donryu rats (Crj-Donryu; Nippon Charles-River, Yokohama,
Japan), 8–10 weeks old and with an average weight of 250–300g,
were used for all experiments. Rats were bred and maintained in a
ventilated, temperature-controlled (24711C), specific pathogen-
free environment on a bed of wood shavings with food and water
freely available and a 12-h light–dark cycle. They were usually
housed two or three per cage. The rats equipped with transparent
chambers for microscopic observations (see below) and the rats
fitted with diffusion chambers for measurements of TIFP (see
below) were caged singly.
Tumour cell lines included LY80, which is a variant of the
Yoshida sarcoma, and Sato lung carcinoma (SLC), which is an
undifferentiated lung carcinoma. In our laboratory, LY80 and SLC
are maintained by successive i.p. and s.c. transplantations,
respectively. Although SLC and LY80 showed almost the same
growth potential in the transparent chamber and showed almost
the same reaction after AC7700 administration, we chose SLC
rather than LY80 for vital microscopic observations. We did so
because when SLC is growing in transparent chambers, demarca-
tion between the edge of the growing tumour and the normal tissue
is clear (Hori et al, 1995), and therefore the change in normal
arterioles and tumour vessels after AC7700 administration can
easily be recognised.
All experimental protocols were reviewed by the Committee on
the Ethics of Animal Experiments in our institute and were carried
out in accordance with Guidelines for Animal Experiments issued
by Tohoku University School of Medicine and The Law (No. 105)
and Notification (No. 6) issued by the Japanese Government. The
ethical guidelines that were followed meet the standards required
by the UKCCCR (Workman et al, 1998) guidelines.
Tumour cell implantation
LY80 cells growing in ascites of a donor rat were collected,
suspended in pH 7.4 phosphate-buffered saline, and adjusted to a
concentration of 2 10
6 cells per 0.1ml or 10ml. Recipient rats
were anaesthetised with diethyl ether (Wako Pure Chemical
Industries, Ltd, Osaka, Japan). For the investigation of topical
application of the drug to the tumour tissue, and for the
experiment measuring TIFP using the wick-in-needle method,
the tumour cell suspension was injected s.c. into the back of each
rat. For measuring TIFP by the diffusion chamber method, the
chamber was first implanted in the back of the rat and then a
suspension (0.1ml) containing 2 10
6 cells was injected around
the chamber. For the experiment investigating the effect of intra-
arterial (i.a.) AC7700 injection, tumour cells were implanted into
the kidney. Recipient rats were anaesthetised and placed in the left
lateral decubitus position, and a vertical incision was made in the
right flank through the skin and peritoneum to expose the lateral
aspect of the kidney. The tumour cells (2 10
6 cells in 10ml) were
implanted into the renal parenchyma using a 50-ml graduated
syringe (Hamilton Co., Reno, NV, USA) and a 27-gauge syringe
needle (27G; Termo Co., Tokyo, Japan). The site of injection was
2mm below the renal capsule. The hole made by the needle was
sealed with synthetic resin glue (Aron Alpha 201; Toagosei
Chemical Industry Co., Tokyo, Japan). After the injection, the
incision wound was closed in one layer with thread, and the
animals were allowed to recover.
Drugs
AC7700 (AVE8062), one of the combretastatin derivatives, was
synthesised and provided by Ajinomoto Pharmaceutical Research
Laboratories, Kawasaki, Japan. The AC7700 powder was dissolved
in 0.9% NaCl solution immediately before use. The AC7700
solution was usually injected into the tail vein at a rate of
0.15mlmin
 1 using an infusion pump (Compact Syringe Pump;
Harvard Apparatus Co., Inc., Millis, MA, USA). In all experiments
of the present study, the AC7700 administration was completed
within 2min. The solution volume administered was 1mlkg
 1.
Fluorescein isothiocyanate dextran (molecular weight (m.w.)
4400Da) (FITC-dextran, Sigma Chemical Co., St Louis, MO,
USA) was used as a fluorescent contrast material. Experiments
were performed with the animals anaesthetised in a temperature-
controlled (24711C) box fitted with a suction duct. Both
pentobarbital sodium salt (Tokyo Kasei Kogyo Co., Ltd, Tokyo,
Japan) and enflurane (Ethrane; Abbott Laboratories, North
Chicago, IL, USA) were used simultaneously for anaesthesia. The
pentobarbital powder was solved in distilled water (Otsuka
Pharmaceutical Co., Ltd, Tokyo, Japan) to give a concentration
of 50mgml
 1 and was administered intramuscularly (i.m.) at a
dose of 30mgkg
 1 10min before the experiment. When the
experiment continued for more than 2h, supplemental doses
(15mgkg
 1 i.m.) were given at 90-min intervals to maintain
immobilisation. Enflurane concentration was maintained at 1% in
the inhaled carrier gas, which was administered at a rate of
1lmin
 1 by means of an anaesthetic apparatus for small
laboratory animals (Hori et al, 1991). We certify that this
anaesthetic condition did not change blood pressure and TBF
significantly throughout the experiment of 6h (Hori et al, 2002).
Measurement of TBF
The tumour blood flow was measured using the hydrogen
clearance method (Hori et al, 1991, 1996, 2002) that was originally
developed by Aukland et al (1964). The blood flow measured by
this method is not the total blood flow (Gullino and Grantham,
1961); rather, it is the local blood flow (Peterson, 1979). In brief,
after saturation of the tissue with hydrogen following inhalation of
9% hydrogen gas in air (at 1lmin
 1), the blood flow value (in
mlmin
 1 (100g tissue)
 1) in a small region was calculated from
the half-life of the clearance curve obtained. A tissue blood flow
meter with two separate amplifiers (PHG-201; Unique Medical Co.,
Tokyo, Japan) was used. Two 80-mm-diameter hydrogen electrodes
(UHE-201C; Unique Medical) and two rod-type Ag/AgCl reference
electrodes (TT-98012; Unique Medical) were usually used for each
rat. The reference electrodes were inserted between the skin and
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smusculature in the caudal region. In the experiment measuring
TIFP, one electrode was used to monitor TBF. In the experiment
measuring TBF change after topical application of AC7700, a
special electrode (see below) was used.
The tumour blood flow was measured 7–10 days after tumour
implantation. For measuring TBF in the kidney tumour, a vertical
incision was carefully made in the right flank through the skin and
peritoneum, similar to the incision for implantation of the tumour,
and electrodes were inserted into the solid tumour growing in the
renal parenchyma, to a depth of 2mm from the tumour surface.
Throughout the experiment, rats were placed prone on a heated
stage at 341C and kept in the same position. The rectal temperature
monitored with a thermistor for small animals (PTC-201; Unique
Medical) was 33.5–35.51C and the condition was maintained.
Measurement of mean arterial blood pressure
The mean arterial blood pressure (MABP) was monitored in all
rats in which TBF was measured. The mean arterial blood pressure
was measured via a catheter (PE-50; Clay Adams, Persippany, NJ,
USA) inserted into the right femoral artery. Pressure in the
catheter was recorded with a pressure transducer (TNF-R;
Spectramed Medical Products, Singapore), the output of which
was fed into an amplifier (6M82; NEC-Sanei Co., Tokyo, Japan)
adapted for such a measurement.
Development of a novel electrode for measuring changes in
local blood flow after topical application of AC7700
To investigate whether tumour vessels or normal vessels are more
sensitive to AC7700, we constructed a new type of wire electrode
for use in the hydrogen clearance method. From the tip of the wire,
a section 1–10mm long is enveloped by a thin polyethylene tube
(outer diameter, 180mm). The sensitive part of the electrode is the
1-mm tip, which detects hydrogen gas. At 10mm from the tip, the
wire is passed through a pinhole made in the sidewall of the tube.
The pinhole is packed with silicone rubber. With this electrode, we
were able to measure the dose–response relationship for AC7700.
Topical application of AC7700 and 0.9% NaCl solution into
tumours and normal s.c. tissue
For tumours, the tip of the electrode was placed at a depth of 4mm
below the tumour surface. For normal tissue, the electrode was
introduced subcutaneously into the animal’s back via a syringe
needle (18G, Termo Co.). The tail end of the polyethylene tube was
connected to a 50-ml graduated syringe (Hamilton Co.). Through
this tube, 10ml of AC7700 solution (0.2, 1, 10, or 50mgml
 1)o r
10ml of 0.9% NaCl solution was dropped directly on the region at
which blood flow would be measured.
Before the topical application of each solution, blood flow was
measured twice at 30-min intervals. When the blood flow had
stabilised, the solution was dropped on the region of measurement,
and 30min later the blood flow was measured again. The rate of
change of blood flow (%) was calculated from the values before
and 30min after the topical application of the solution.
For direct observation of the contraction of normal arterioles
caused by AC7700, intravital microscopy was used to drop 10mlo f
0.2mgml
 1 AC7700 solution on the vessels of the s.c. tissue, and
the measurements were recorded.
Comparison of changes in TBF induced by i.a. and i.v.
administration of AC7700
For this comparison, LY80 cells (2 10
6) were implanted in the
right kidney as described earlier. At 7–10 days after the
implantation, the second incision was made at exactly the same
incision site as that of the first incision, the kidney was exposed,
and hydrogen electrodes were inserted into the tumour growing
there. Next, a polyethylene tube with an outer diameter of 0.61mm
(PE10; Clay Adams) was inserted into the left common carotid
artery until the tip of the tube reached a position 2–3mm
upstream of the right renal artery. All incision wounds were
sutured with thread or were closed with synthetic resin glue (Aron
Alpha 201). Certain animals in the i.v. injection group also
underwent this operation as a sham operation.
In both the i.a. injection group (n¼6) and the i.v. injection
group (n¼6), 10mgml
 1 AC7700 was infused at a rate of
0.15mlmin
 1 using a microinfusion pump (Harvard Apparatus
Co.). The final dose administered was 10mgkg
 1. After adminis-
tration of AC7700, TBF was measured at multiple time points (i.e.
10, 30, and 60min and every subsequent 1h) for 6h. In another
experimental group, AC7700 was administered i.a. to rats at a dose
of 0.5 and 1mgkg
 1.
Transparent chamber assays
For direct observation of changes in normal arterioles and tumour
vessels caused by AC7700, transparent chambers (Hori et al, 1990)
were implanted in dorsal skin flaps of rats under aseptic
conditions. The chamber used in the present experiment was a
‘sandwich’ system (Yamaura and Sato, 1974) in which each
chamber consists of a pair of identical titanium frames containing
a circular quartz glass window 300mm thick. The method of
implantation of the chamber has been previously described in
detail (Hori et al, 1981, 1990).
Method of assignment of orders to arterioles
In the s.c. tissue of the rat, arterioles, terminal arterioles, and
certain capillaries could be ordered according to Strahler’s (1957)
nomenclature, which is a purely topological method and has been
used extensively in various applications, such as for rivers, trees,
and blood vessels. Strahler’s method is as follows: when two
segments of the same order join, the parent segment is assigned
the next higher order. If two daughter segments that have different
orders are joined, the parent segment retains the higher of the two
orders. In our experiments, capillaries originally branching off
from terminal arterioles classified by Wiedeman (1984) were
assigned order 1. Once those capillaries were defined as order 1,
terminal arterioles were assigned order 2 (Hori et al, 1990).
According to this nomenclature, the orders of arterioles were
named a2, a3, a4, and so on, as one moves stepwise from the
terminal arteriole upward.
Vessel classification within a tumour vascular network
Tumour vessels within a transparent chamber were classified into
one of the following three groups on the basis of their anatomical
position and function: (a) feeding arterioles, which supply blood to
a tumour vascular network; (b) tumour capillaries, which
constitute most of a tumour vascular network and play an
important role in nutrient exchange; and (c) drainage vessels,
which drain blood from a tumour vascular network. We previously
reported that TBF is controlled by modified a2 vessels (Hori et al,
1990). That is, feeding vessels are a2 arterioles modified by the
tumour. The diameter of the vessels becomes wider compared to
a2 arterioles. We observed in preliminary experiments that these
three vessel groups can be differentiated according to their
reactions to AC7700.
Intravital microscopic observation of changes in tumour
vessels and TBF caused by AC7700
After anaesthesia, a rat with a transparent chamber was placed in
the right lateral position on a heated stage (MATS-SFA; Tokai HIT
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sCo., Ltd, Tokyo, Japan) at 34.51C, which was attached to the
mechanical stage of the microscope. AC7700 (10mgkg
 1) was
administered via the lateral tail vein using an infusion pump
(Harvard Apparatus Co.). The changes in TBF and the tumour
vascular network were directly observed via a light microscope
(Eclipse E800; Nikon Corp., Tokyo, Japan) with a  10 ocular (CFI
UW; Nikon) and  2-20 objectives (CFI Plan Fluor; Nikon Corp.).
Tumour vessels within the chamber were transilluminated by a 12-
V 100-W halogen lamp. The microscopic image was recorded
using a closed-circuit video system consisting of a CCD video
camera (CS-900; Olympus Kogaku K.K., Tokyo, Japan), a TV
monitor (PVM-14M4J; Sony Corp., Tokyo, Japan), and an S-VHS
video recorder (SVO-2100; Sony).
For intravital fluorescence microscopic observation, the light
source was changed to a 100-W mercury lamp. A solution of 2%
FITC-dextran (m.w. 4400Da) was injected into the rat as a single
i.v. bolus. Tumour vessels within the chamber were epi-illuminated
through a primary filter (420–490nm), a 505-nm dichroic
interference mirror, and a 520-nm barrier filter. The fluorescein
microscopic images were photographed using a silicone-intensi-
fied video camera (C2400-08, Hamamatsu Photonics, Hamamatsu,
Japan).
A video timer was superimposed on the images for record
keeping. Segments of the videotape containing desired images were
transferred to the hard disk of a computer (Power Macintosh 8600/
200, Apple Japan, Inc., Tokyo, Japan) through a video frame
grabber board (IQ-V50PCI, Hamamatsu Photonics). Final images
were output by a digital printer (Pictography 4000, Fuji Photo Film
Co., Ltd, Tokyo, Japan).
Measurement of arteriole and drainage diameters
Intravital microscopic observation for diameter measurements was
performed under  200 magnification. Changes in arteriole and
drainage diameters caused by AC7700 were measured directly on
the TV monitor. The rate of change in the diameter before and
after the administration of AC7700 was calculated.
Histological investigation of changes in tumour capillaries
caused by AC7700
To confirm the presence of functioning tumour vessels, 2% FITC-
dextran was injected i.v. with the use of intravital microscopy.
When FITC-dextran disappeared from the tumour tissue 120min
later, 10mgkg
 1 AC7700 was administered. FITC-dextran was then
injected 30min after the AC7700 administration to demonstrate
complete loss of circulatory function in the tumour vascular
network. After an additional 90min, the glass window of one side of
a transparent chamber was gently removed from the rat, 15%
formalin solution was put directly on the tissue (approximately
150mm thick), and the thin tissue was fixed before killing. The
tissue was processed and embedded in paraffin. Sections (4mm
thick) were cut in parallel to the surface of the membrane tissue
within the transparent chamber and were stained with haematoxylin
and eosin. Changes in microvessels caused by AC7700, in particular,
changes in tumour vascular lumens, were carefully assessed.
Changes in TIFP caused by AC7700
The tumour interstitial fluid pressure was measured by two
different methods – the diffusion chamber method and the wick-
in-needle method. Systemic arterial pressure and TBF were also
simultaneously measured in both methods.
Diffusion chamber method. We previously reported this method
in detail (Hori et al, 1986). The apparatus fitted to the subcutis is
composed of a diffusion chamber with a pore size of 0.45mm,
developed originally by Gullino et al (1964), and a pair of
perforated aluminium shields for fixing its position in the subcutis.
The chamber was inserted into the s.c. tissue of the caudal portion
of the skin flap. After insertion of the chamber, a suspension
(0.3ml) containing 2 10
6 LY80 tumour cells was injected s.c.
around it. The chamber was completely enveloped in the LY80
tumour approximately 1 week after transplantation of tumour
cells. The TIFP was recorded electrically with a transducer
(Spectramed Medical Products) through the polyethylene tube
connected to the diffusion chamber. The tumour interstitial fluid
pressure was serially measured and recorded before and after
AC7700 administration.
Wick-in-needle method. Measurement of TIFP by the wick-in-
needle method was performed using the technique reported by
Scholander et al (1968). In the present study, we used the wick-in-
needle device made from a 23-gauge syringe needle (23G, Termo
Co.). The needle was inserted into the solid tumour, and the other
end of the device was connected to a pressure transducer
(Spectramed Medical Products) by a polyethylene tube. The
tumour interstitial fluid pressure was serially measured and
recorded before and after the administration of AC7700 as in the
diffusion chamber method.
Statistics
All results are expressed as means7s.d. The statistical significance
of the difference in the blood flow reduction rate caused by topical
application of each concentration of the AC7700 solution between
tumours and normal s.c. tissue, and among the tumours or normal
s.c. tissues, was evaluated with an unpaired two-group t-test. The
significance of the difference in TBF reduction at each time point
between i.v. and i.a. administration of AC7700 was evaluated with
repeated measures ANOVA. Comparisons of the difference of
diameter of arteriolar vessels before and after AC7700 adminis-
tration were made by using paired two-group t-tests. P-values of
0.05 or lower were considered significant.
RESULTS
Topical application of AC7700 or 0.9% NaCl solution to
tumours and normal s.c. tissues
Blood flow values measured by the special electrodes developed for
topical application were not significantly different from those
measured by electrodes that have been used so far (data not
shown), which indicated that the slight increase in the diameter of
the electrodes because of the covering wire did not greatly
influence the blood flow measurement. When 10ml of the control
(0.9% NaCl) solution was dropped directly at the site of blood flow
measurement, the flow signal increased in a transient manner as an
artefact; however, the blood flow returned to its original value
within 5min. Each blood flow response caused by topical
application of each concentration of AC7700 was reproducible.
Figure 1A shows changes in local blood flow when 10mlo f
various concentrations (0.2, 1, 10, or 50mgml
 1) of the AC7700
solution or 10ml of 0.9% NaCl solution was dropped directly at the
site of blood flow measurement in normal s.c. tissues and s.c.
tumours. Local blood flow of the normal s.c. tissues decreased
significantly and dose dependently because of AC7700 (0.9% NaCl
vs 0.2mgml
 1 AC7700, P¼0.0116; 0.9% NaCl vs 1mgml
 1
AC7700, Po0.0001; 0.9% NaCl vs 10mgml
 1 AC7700,
Po0.0001). In contrast, local blood flow of LY80 tumours did
not change significantly at any concentration of AC7700 (0.9%
NaCl vs 0.2mgml
 1 AC7700, P¼0.3445; 0.9% NaCl vs 1mgml
 1
AC7700, P¼0.0706; 0.9% NaCl vs 10mgml
 1 AC7700, P¼0.0690).
The TBF did decrease significantly with 50mgml
 1 AC7700
(P¼0.0002).
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sThe concentration of AC7700 needed to reduce blood flow to
one-half of the original value was 50mgml
 1 in tumour tissue,
whereas only 1mgml
 1 was sufficient in normal tissue. That is, the
sensitivity of the blood flow response after topical application of
AC7700 was markedly higher in normal vessels relative to the
tumour vessels. Even at the concentration of 0.2mgml
 1, when
AC7700 was applied directly to normal s.c. tissue, arterioles first
constricted (Figure 1B) and the local blood flow decreased by
approximately 30% (Figure 1A). In contrast, when the same
concentration and volume of AC7700 were used for tumour tissue,
TBF did not show significant changes (Figure 1A).
Comparison of the changes in TBF induced by i.a. and i.v.
administration of AC7700
A comparison of changes in TBF after i.v. and i.a. administration
of 10mgkg
 1 AC7700 is shown in Figure 2. There was no
significant difference between the two groups (P¼0.0765). Intra-
arterial administration of AC7700 did not have stronger effects
than i.v. administration. For a dose of 1mgkg
 1 AC7700 or lower,
i.a. administration did not induce a prominent decrease in TBF
(data not shown).
Changes in the diameter of host arterioles and tumour-
feeding vessels caused by i.v. administration of AC7700
Table 1 shows changes in the diameter of arteriolar vessels and
tumour-feeding vessels caused by AC7700. When 10mgkg
 1
AC7700 was given i.v., all orders of arterioles within a transparent
chamber showed significant vasoconstriction (a4, a3, and a2,
Po0.0001). The changes in diameters of a4, a3, and a2 vessels
30min after AC7700 administration were  29.2,  33.6, and
 47.2%, respectively. The blood flow in tumour-feeding vessels
(modified a2 arterioles) ceased completely, and the vessels
disappeared from view. Thus, it was impossible to measure the
diameter of these vessels after AC7700 administration. The blood
flow in normal tissue did not stop.
Process of irreversible stasis of TBF caused by AC7700
A typical intravital microscopic finding showing the process of
change in tumour microcirculation caused by AC7700 is shown in
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Figure 1 Changes in blood flow induced by topical application of
AC7700 or 0.9% NaCl solution to tumours and normal s.c. tissues (A)A
sample of 10ml of AC7700 solution at each concentration (0.2, 1, 10, and
50mgml
 1) and of 0.9% NaCl solution was dropped on the region of
blood flow measurement in tumour and s.c. tissue.The blood flow was
measured before and 30min after application of the solution, and the rate
of change in blood flow (%) was calculated. Black bars, normal s.c. tissue;
hatched bars, tumour. For each concentration of AC7700 and 0.9% NaCl
solution, nine and seven rats were used for measurements in normal s.c.
tissues and tumours, respectively. At concentrations of 1 and 10mgml
 1,
the sensitivity of normal s.c. tissue to AC7700 was significantly higher than
that of tumour tissue. (B) vital microscopic images of changes in arterioles
after topical application of 10ml of 0.2mgml
 1 AC7700. Note that an
arteriole (arrows) was markedly constricted by AC7700: (a) before droplet
application; (b) 19s after droplet application.
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Figure 2 Comparison of changes in TBF after i.a. and i.v. administration
of AC7700. AC7700 administration (10mgkg
 1) was completed at 0min.
The difference in TBF reduction between the two routes of AC7700
administration was not significant (P¼0.0765): K, i.a. route (n¼12); J,
i.v. route (n¼11).
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sFigure 3. When AC7700 was administered i.v., a3 and a4 arterioles
near the tumour constricted (Figure 3B), and then MABP increased
by 38%. The blood flow in tumour-feeding vessels (asterisk in
Figure 3A) began to decrease immediately after AC7700 admin-
istration and stopped completely 30min later. As a result, the TBF
in the numerous tumour capillaries that formed the tumour
vascular network ceased completely.
When FITC-dextran was administered by a single bolus i.v.
injection before AC7700 administration, the fluorescent dye
reached the tumour vessels (Figure 4A). Many tumour vessels
had diameters of 50–100mm. However, 30min after AC7700
administration FITC-dextran did not reach the tumour vessels at
all (data not shown) because of complete blockage of the tumour
microcirculation. A histological section of the same area of the
tumour tissue, which was locally fixed by 15% formalin before
Figure 3 Process of irreversible TBF stasis caused by AC7700: (A) before 10mgkg
 1 AC7700 administration; (B) 30min after the end of drug
administration; (C) 2h later; (D) 2.5h later. (E) Enlargement of a section of D.( A–D) Photograph with the  10 the eyepiece and the  4 objective (bar,
500mm); (E) photograph with the  10 the eyepiece and the  20 the objective (bar, 100mm). Arterioles (arrows) and a feeding arteriole (*) showed
marked contraction induced by AC7700. Tumour blood flow stopped completely 30min after i.v. AC7700 administration, and many erythrocytes were
trapped in drainage vessels located at the tumour periphery. Dramatic haemolysis occurred in those tumour vessels 2–2.5h after drug administration (C,
D). Haemorrhage was not observed (E). Reperfusion of blood into these tumour vessels was never seen.
Table 1 Effects of AC7700 on vessel diameter in each vascular segment
in s.c. tissue
a
Vessel diameter (lm)
Vessel type n
Before
AC7700
30min after
AC7700
Change
(%)
a4 10 50.7710.6 35.978.3
b  29.2
a3 18 30.778.3 20.476.3
b  33.6
a2 7 21.474.5 11.372.5
b  47.2
Feeding vessel 6 37.274.8 —
c
aVessel diameter was measured before and 30min after administration of 10mgkg
 1
AC7700. Values are expressed as means7s.d. Eight rats were used. n¼number of
measurements.
bPo0.0001.
cImpossible to measure.
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skilling, is shown in Figure 4B. It should be noted that the vascular
lumens of the tumour vessels narrowed or disappeared after
AC7700-induced TBF stasis, and many vessels had a fine, thread-
like appearance (Figure 4B, arrows).
The drainage of the tumour vascular bed, which was located at
the periphery of the tumour and frequently had a sinusoid-like
structure, often showed a gradual decrease in plasma volume, and
many erythrocytes remained there (Figure 5). After 2–3h,
erythrocytes left in these drainage vessels underwent haemolysis
(Figure 3C and D), resulting in passive enlargement of vascular
diameter and thrombosis in the vessel lumens (Figure 3E). Once
haemolysis-induced thrombosis occurred, the TBF never recov-
ered. These phenomena were observed in all 12 tumours viewed in
the transparent chambers, without exception. The change in the
diameter of drainage vessels was þ31.0711.4% (11 chambers).
In normal vessels, however, the blood flow did not stop after i.v.
administration of 10mgkg
 1 AC7700. Even if the blood flow
completely disappeared after death, the vascular lumen in the
arterioles, true capillaries, and venules remained open (Figure 6).
Especially noteworthy is the fact that even in the true capillaries
with diameters of 15mm or less, the vascular lumen did not close
(Figure 6C).
Effect of AC7700 on TIFP
Diffusion chamber method. When a diffusion chamber was
implanted in the s.c. tissue of the back of a rat and a tumour
cell suspension was injected around the chamber, the chamber
was completely enveloped in the growing tumour 1 week later.
Figure 7 shows the simultaneous changes in MABP, TIFP, and TBF
(n¼5) caused by 10mgkg
 1 AC7700. The mean tumour size,
MABP, TIFP, and TBF at the start of measurement were
3.570.4cm
3, 96.477.1mmHg, 10.571.6mmHg, and
23.5716.6mlmin
 1(100g)
 1, respectively. When AC7700 was
administered i.v., MABP increased, and TBF and TIFP simulta-
neously decreased. The MABP, TIFP, and TBF 30min after AC7700
administration were 120.074.0mmHg, 4.870.5mmHg, and
2.571.7mlmin
 1 (100g)
 1, respectively. These parameters did
not change at all after i.v. administration of 0.9% NaCl solution
(data not shown). Changes in MABP, TIFP, and TBF induced by
AC7700 were all significant (MABP, P¼0.0022; TIFP, P¼0.0007;
TBF, P¼0.0388).
Wick-in-needle method. At the start of measurement using the
wick-in-needle method, the mean tumour size was 6.473.0cm
3
(n¼6). After i.v. administration of 10mgkg
 1 AC7700, MABP
significantly increased from 95.277.8 (before the drug) to
Figure 4 Disappearance of tumour vascular lumens caused by AC7700-
induced TBF stasis. (A) Fluorescence angiography. To confirm functioning
tumour vessels, 2% FITC-dextran (m.w. 4400Da) was administered by a
single bolus i.v. injection. Before AC7700 administration, the fluorescent
dye did reach the tumour vessels. Many tumour vessels had diameters of
50–100mm. Bar, 250mm. (B) histology of the same area 120min after
administration of 10mgkg
 1 AC7700. The tumour tissue within the
chamber was locally fixed by formalin before killing. Many tumour vessels
greatly constricted or the vascular lumens disappeared, and the vessels
showed a fine thread-like appearance. We confirmed this finding by serial
section of the tissue. Bar, 50mm.
Figure 5 Stagnation of blood cells in the drainage vessels caused by
AC7700: (A) before administration of 10mgkg
 1 AC7700; (B) 30min
after AC7700 administration. The plasma volume in tumour vessels
gradually decreased, and many erythrocytes remained in the vessels. Bar,
100mm.
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s137.3710.7mmHg (30min after administration) (Po0.0001),
TIFP significantly decreased from 12.173.1 (before) to
7.172.3mmHg (30min after) (P¼0.001), and TBF significantly
decreased from 30.276.1 (before) to 5.571.9mlmin
 1 (100g)
 1
(30min after) (Po0.0001). The results obtained by this method
supported those of the diffusion chamber method.
DISCUSSION
We conclude that TBF stasis brought about by AC7700 adminis-
tration most likely results from an indirect action involving the
contractile response of arterioles, rather than a direct effect of this
drug on tumour vessels. Our experiments in the present study
strongly support this conclusion.
In the first experiment, the sensitivity of vessels in tumours to
topical application of AC7700 was compared with that of vessels
in normal s.c. tissue. Normal tissue was more sensitive than
tumour tissue to this agent. When blood flow volume was
measured via the hydrogen clearance method, what was actually
measured was not the total blood flow (Gullino and Grantham,
1961), but the local blood flow (Peterson, 1979). The electrodes
used in the experiment measured blood flow around the 1-mm
tip of the electrode. After application of AC7700 to the region of
measurement, notable changes in TBF were not found with
concentrations up to 10mgml
 1. In normal tissue, however,
there was strong constriction of the arterioles with 1mgml
 1
AC7700, as well as a large decrease in blood flow in the
capillary bed. We therefore conclude that the small changes in
TBF were not due to an insufficient volume of AC7700 having been
applied to the region, but instead were due to the relatively low
sensitivity of the tumour vessels themselves. Thus, it was strongly
suggested that the stasis of TBF induced by AC7700 administration
was not caused by a direct effect of the drug on the tumour
vasculature.
In the second experiment, the effects of i.v. and i.a. adminis-
tration of AC7700 were compared. If AC7700 works directly on
tumour vessels, then the stasis effect after arterial administration –
leading to a high concentration of AC7700 reaching the tumour –
should be stronger than that after venous administration. In fact,
stronger stasis was not obtained with i.a. administration. This
finding strongly suggests that the site of AC7700 action is not the
luminal surface of tumour vessels.
The results of the above experiments indicate that the primary
action of AC7700 is not on the tumour vasculature. If that is the
Figure 6 Normal microvessels after the administration of AC7700: (A)
true capillaries (arrows); (B) arteriole (arrow) and venule (arrowhead); (C)
arteriole and precapillary vessel (arrow). Bars, 100mm. Haematoxylin and
eosin staining. A rat with a transparent chamber was killed 2h after the
administration of 10mgkg
 1 AC7700. The tissue was resected, and routine
histological studies were performed. Note that the vascular lumens of the
normal arterioles, venules, and even true capillaries (with diameters of 10–
15mm) remained open after AC7700 administration.
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Figure 7 Simultaneous changes in TIFP, MABP, and TBF caused by
AC7700. J, TIFP; K, MABP; &, TBF. AC7700 administration
(10mgkg
 1) was completed at 0min. Note that TIFP markedly decreased,
together with a TBF decrease, immediately after AC7700 administration.
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scase, then why indeed does AC7700 bring about TBF stasis and
why does not the stopped TBF subsequently recover? To answer
these questions, we used a rat transparent chamber to observe the
effects of AC7700 on host arterioles and the tumour vascular
network.
We previously reported that the fact that the sites of increased
vascular resistance differ with each vasopressor is the primary
reason why various vasopressors produce different changes in TBF
(Hori et al, 1993). Increases in arteriolar resistance upstream cause
a decreases in the perfusion pressure of tumour-feeding vessels
downstream. In the present study, AC7700 constricted a3 and a4
arterioles upstream, leading to increases in arteriolar resistance. In
fact, TBF decreased continuously, blood flow stopped completely
after 30min of AC7700 administration, and the vessels themselves
disappeared from sight. However, we also confirmed that when a
small dose of AC7700 was used, the increased resistance of
arterioles disappeared in 2–3h, and the blood flow to the vessels
feeding the tumour recovered (data not shown). We therefore
conclude that the TBF stasis effect of AC7700 is triggered by
continued constriction of host arterioles. It is not yet clear from
the present studies alone as to why AC7700 constricts host
arterioles. We consider that the receptor for AC7700 may be on the
vascular smooth muscles. Further studies are necessary to
demonstrate the hypothesis.
When blood flow in tumour-feeding vessels is stopped, that
effect is immediately transmitted to the tumour capillaries. Before
AC7700 administration, when TBF was strong, many vessels with
diameters larger than 50mm were seen; subsequent to drug
administration, these vessels had greatly constricted vascular
lumens or completely disappeared. It is thought that this effect is
caused by structural characteristics of tumour vessels, that is,
tumour vessels are composed fundamentally of one layer of
endothelial cells (Papadimitriou and Woods, 1975; Konerding et al,
1989), or that, even when many pericytes and smooth muscle cells
are present around the tumour vessels, the binding between the
tumour endothelial cells and pericytes or smooth muscle cells is
weak (Morikawa et al, 2002). In general, the endothelium of
tumour vessels is stretched, such that the vascular wall is extremely
thin, and intravital microscopic observations have shown that
lumen morphology is maintained with difficulty. The reason for
the observation of many thread-like tumour vessels after AC7700
administration is that tumour vessels are fundamentally passive
vessels, so that they dilate when blood flow increases and constrict
when blood flow decreases. The constriction or disappearance of
the lumen of tumour vessels clearly poses a significant resistance
to reperfusion.
In contrast, in the case of normal capillaries, even when
there is a decrease in blood flow the vascular lumen does not
collapse, and the normal morphology is maintained. This finding
was confirmed by observations of both intravital microscopic
samples and tissue samples fixed in formalin. Such results are
thought to be a consequence of both a strong binding between
the endothelial cells and pericytes of normal capillaries and
the strong structural support provided by a continuous
basement membrane (Simionescu and Simionescu, 1984). Even
when blood flow is temporarily blocked, reperfusion will not
encounter a large resistance, provided that the vascular lumen is
not destroyed.
The most dramatic change seen after AC7700 administration
was in the drainage of the tumour vascular bed, which frequently
has a sinusoid-like structure. In that region, blood flow is usually
not rapid, and the administration of AC7700 led to further slowing
and sluggishness. Ultimately, TBF stopped completely, and many
erythrocytes stagnated there. After 2–3h, those erythrocytes
underwent haemolysis, resulting in thrombosis in the lumens of
the drainage tumour vessels. It is well known that one of the causes
of blood stasis is the formation of thrombus. Nilsson et al (2001)
reported that tissue factor induces intratumour thrombus forma-
tion, resulting in the cessation of blood flow and widespread
necrosis within the tumour. In the case of AC7700 administration,
however, the first effect is blood flow cessation, followed by
thrombus formation within the lumens of the drainage tumour
vessels because of haemolysis.
Even after 2h of occlusion of tumour-feeding vessels, recovery
of blood flow is possible (data not shown), but if haemolysis occurs
in the drainage region the TBF stasis becomes irreversible. Since
haemolysis acts as a vascular toxin and is likely to be a cause of
vascular destruction, it is thought to be the direct cause of
irreversible TBF stasis. The precise reason for the haemolysis
remains uncertain, and additional studies of this phenomenon are
needed.
Recently, Tozer et al (2001, 2002) reported a mechanism of the
stoppage of TBF brought about by CA-4-P, in which they
emphasised the importance of the increase in TIFP. It was
previously reported that TIFP increases together with tumour
proliferation (Paskins-Hurlburt et al, 1982; Wiig et al, 1982; Hori
et al, 1986; Jain, 1987). In some cases, it also increases after
chemotherapy and radiotherapy (Roh et al, 1991; Curti et al, 1993).
The increased TIFP due to increased tumour vascular permeability
in turn is thought to compress tumour vessels and bring about
decreases in TBF. In fact, Tozer et al (2001) demonstrated in in
vivo experiments that CA-4-P increased tumour vascular perme-
ability. Moreover, in the process of increasing permeability, CA-4-
P bound to tubulin and was surmised to be involved in causing the
cytoskeletal disorganisation of the endothelium (Dark et al, 1997;
Grosios et al, 1999). Although these authors did not actually
measure the TIFP, they argued that an increase in vascular
permeability necessarily leads to an increase in TIFP. Eikesdal et al
(2002), however, reported that in BT4An rat gliomas, CA-4-P did
not produce an increase in TIFP. These conflicting findings suggest
that there may be differences in tumour vascular permeability and
TIFP brought about by CA-4-P that are related to the type of
tumour.
Tozer et al (2001) also reported that there is no reduction in
arteriolar or venular diameter at early times after i.v. administra-
tion of CA-4-P. In the case of AC7700, active constriction of
arterioles was observed immediately after drug administration.
Constriction of arterioles soon led to a decrease in blood flow in
the tumour-feeding vessels. As there was a marked decrease in the
volume of fluorescent dye reaching the tumour vessels as a result
of the decrease in TBF (data not shown), we were unable to
determine directly whether an increase in tumour vessel perme-
ability followed AC7700 administration. However, the fact that
there was an immediate, marked decrease in TIFP strongly
suggests that AC7700 induced no increase in the permeability of
tumour vessels. We surmise that AC7700 strongly constricts
tumour-feeding vessels, and as a consequence of the marked
suppression of the volume of water flowing into the tumour, a
decrease in TIFP occurs.
The finding that CA-4-P does not immediately constrict the
arteriolar system whereas AC7700 immediately constricts it
suggests that their similar chemical structures result in similar
effects via different responses in the vascular system. That the
pharmacological effects of these two similar drugs differ, or that
sometimes the drugs produce opposite effects, is not unusual in
pharmacology. For example, it is well known that both epinephrine
and isoproterenol are catecholamines with similar structures, but
they produce diametrically opposed effects on peripheral vascular
resistance. It would therefore not be surprising if AC7700 and CA-
4-P also have different mechanisms of action.
In light of the experimental findings obtained in the present
study, we can summarise the effects of AC7700 as producing TBF
stasis that, in turn, brings about necrosis of solid tumours, as
shown in Figure 8. To obtain the widespread necrosis of tumour
tissue as a result of TBF stasis, it is necessary and sufficient to close
the entrance to the tumour vascular bed for more than 2h and to
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socclude the exit routes via haemolysis. We have already
demonstrated this effect by using drugs other than AC7700 and
will report those results elsewhere. In the present study, we
clarified the microcirculatory mechanism by which AC7700 brings
about irreversible stasis of TBF, leading to tumour necrosis. In the
future, it will be necessary to clarify at the molecular levels, using
immunohistochemistry, whether there is an AC7700 receptor in
the smooth muscle cells of blood vessels, and why haemolysis of
erythrocytes trapped within tumour vessels occurs.
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